FDA outside-expert panel reviews evidence to expand ELEVIDYS into a broader Duchenne population. The vote is non-binding; FDA has historically aligned with AdCom recommendations ~75% of the time on biologics. Output: vote tally, panel concerns flagged on the public record.
What’s at stake
ELEVIDYS (delandistrogene moxeparvovec) is a one-time gene therapy for Duchenne muscular dystrophy — a fatal progressive muscle-wasting disease caused by dystrophin gene mutations — developed by Sarepta Therapeutics. The therapy uses a hollow AAVrh74 virus to deliver a shortened but functional microdystrophin gene into muscle cells throughout the body, enabling patients to produce a form of the missing structural protein. ELEVIDYS received accelerated FDA approval in 2023 as the first gene therapy for DMD; Sarepta is pursuing a label expansion to ambulatory patients aged 4 and older.
X-linked genetic disease causing progressive muscle weakness in boys. Median survival in late 20s with current care; gene therapy (ELEVIDYS) is the lead curative approach.
This event was extracted from a primary disclosure. The full chain of citations is in the disclosure trail below.
- AdComregulatoryAdvisory Committee
External panel of expert physicians and patients who vote on whether a drug should be approved. The FDA usually but not always follows the vote.
Genetic Metabolic Diseases
briefing materials posted ~48 hours before the meeting · we cite the FDA URL directly
- Q1Do the available data demonstrate that ELEVIDYS is effective for the proposed indication?
- Q2Is the safety profile of ELEVIDYS acceptable in light of the demonstrated benefit?
- Q3Should the FDA approve ELEVIDYS for the proposed indication based on the totality of evidence?
questions are FDA-issued · committee votes are taken via roll call · we never speculate on outcomes
Each member’s past votes across all committee meetings — sourced from FDA transcripts. Members with disclosed payments from the sponsor are flagged via CMS OpenPayments.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| KRESLADImarnetegragene autotemcel | RCKT | gene therapy | lentiviral ITGB2 transfer (LAD-I) | PDUFA · Oct 26 | |
| VOXZOGOvosoritide | BMRN | peptide | CNP analog (FGFR3 antagonism) | PDUFA · Nov 26 | |
| GALAFOLDmigalastat | FOLD | small molecule | pharmacological chaperone of α-galactosidase A | PDUFA · Nov 26 |
Disclosure trail
- Mar 4, 2026·1mo agopinned · highest confidenceHIGH confFDAEXACTtop claimMAY 222026
“The Cellular, Tissue, and Gene Therapies Advisory Committee will meet on May 22, 2026, to review BLA STN125781 (delandistrogene moxeparvovec — ELEVIDYS) Supplemental.”
contextFDA Advisory Committee Calendar entry, retrieved 2026-03-04.
conf 99%via fda calendar